Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H20N2S |
Molecular Weight | 296.43 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1
InChI
InChIKey=HTMIBDQKFHUPSX-UHFFFAOYSA-N
InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00902Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/methdilazine-hydrochloride.html
Sources: http://www.drugbank.ca/drugs/DB00902
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/methdilazine-hydrochloride.html
Methdilazine is a phenothiazine compound with antihistaminic activity. Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Mycobacterium spp. growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/8103345 |
|||
Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00902 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TACARYL Approved UseUsed in the treatment of pruritus associated with pityriasis rosea. Launch Date1981 |
PubMed
Title | Date | PubMed |
---|---|---|
Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents. | 1988 Jul |
|
Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. | 1993 Jun |
|
Altered membrane permeability as the basis of bactericidal action of methdilazine. | 1998 Jul |
|
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. | 2001 May |
|
Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. | 2005 |
|
Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against Mycobacterium tuberculosis in mice. | 2009 Dec |
|
A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. | 2010 Apr 8 |
Patents
Sample Use Guides
Usual adult and adolescent dose
Oral, 8 mg every six to twelve hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8103345
Methdilazine (Md) could inhibit various Mycobacterium spp. at 5-15 ug/ml concentrations in vitro as well as in vivo.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
||
|
WHO-ATC |
R06AD04
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
||
|
WHO-VATC |
QR06AD04
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081430
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
DB00902
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
14677
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
879
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
METHDILAZINE
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
29648
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
C044642
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
1742
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
7231
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
SUB08844MIG
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
m7306
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
6823
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200959
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
4Q13LY9Z8X
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
C66114
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
1982-37-2
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
DTXSID6023282
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY | |||
|
217-841-6
Created by
admin on Fri Dec 15 16:24:29 GMT 2023 , Edited by admin on Fri Dec 15 16:24:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)